{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Seelos Therapeutics, Inc.
Is Seelos Therapeutics, Inc. overvalued or undervalued?
As of April 15, 2025, Seelos Therapeutics, Inc. has been downgraded to "does not qualify" due to overvaluation and poor performance metrics, including a P/E ratio of 0.00 and a year-to-date return of -100%, making it an unviable investment compared to its peers and the S&P 500.
Is Seelos Therapeutics, Inc. overvalued or undervalued?
As of August 11, 2023, Seelos Therapeutics, Inc. is considered overvalued and rated as "risky" due to its misleading financial metrics, including a P/E ratio of 0.00 and an EV to EBITDA of -0.33, especially when compared to peers like Pieris Pharmaceuticals and OncoCyte Corp.
Is Seelos Therapeutics, Inc. technically bullish or bearish?
As of February 24, 2025, the technical trend is mildly bearish due to daily moving averages and monthly RSI indicating bearish conditions, despite some mildly bullish signals from weekly MACD and KST.
Who are in the management team of Seelos Therapeutics, Inc.?
As of March 2022, the management team of Seelos Therapeutics, Inc. includes Raj Mehra (Chairman, President, CEO, and Interim CFO) and board members Dr. Judith Dunn, Dr. Brian Lian, Daniel O'Connor, and Richard Pascoe.
How big is Seelos Therapeutics, Inc.?
As of December 2023, Seelos Therapeutics, Inc. has an unavailable market capitalization, reported net sales of 2.02 million, a net profit of 4.10 million, negative shareholder's funds of -33.51 million, and total assets of 5.42 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
